千红制药
(002550)
| 流通市值：48.61亿 | | | 总市值：68.34亿 |
| 流通股本：9.10亿 | | | 总股本：12.80亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 461,101,487.65 | 1,814,268,908.89 | 1,465,941,311.21 | 1,056,756,137.67 |
| 营业收入 | 461,101,487.65 | 1,814,268,908.89 | 1,465,941,311.21 | 1,056,756,137.67 |
| 二、营业总成本 | 344,356,267.11 | 1,666,045,224.07 | 1,300,459,887.27 | 936,630,414.3 |
| 营业成本 | 216,068,845.29 | 1,029,333,504.43 | 836,543,435.77 | 614,967,781.22 |
| 税金及附加 | 6,387,200.36 | 20,402,904.09 | 15,081,073.97 | 8,821,950.94 |
| 销售费用 | 78,393,143.31 | 393,856,856.88 | 308,736,457.04 | 217,344,429.03 |
| 管理费用 | 26,160,279.72 | 131,760,590.33 | 93,672,470.7 | 62,822,042.84 |
| 研发费用 | 17,478,054.22 | 97,083,446.01 | 53,171,193.11 | 41,002,111.74 |
| 财务费用 | -131,255.79 | -6,392,077.67 | -6,744,743.32 | -8,327,901.47 |
| 其中:利息费用 | 726,667.2 | 5,926,399.35 | 5,541,658.84 | 3,908,366.16 |
| 其中:利息收入 | 2,018,292.95 | 11,298,061.13 | 8,187,816.38 | 6,181,428.43 |
| 加:公允价值变动收益 | 430,734.45 | 771,381.2 | 440,841.65 | 323,896.28 |
| 加:投资收益 | 3,028,237.13 | 8,004,545.03 | 3,645,414.5 | 945,072.01 |
| 资产处置收益 | - | 25,350,482.59 | 208.74 | - |
| 资产减值损失(新) | - | -19,616,130.84 | -1,390.24 | -1,390.24 |
| 信用减值损失(新) | -6,064,766.43 | 17,427,467.13 | 16,636,515.41 | 8,453,516.1 |
| 其他收益 | 2,868,043.79 | 24,195,093.67 | 8,136,427.17 | 4,836,480.42 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 117,007,469.48 | 204,356,523.6 | 194,339,441.17 | 134,683,297.94 |
| 加:营业外收入 | 1,829.56 | 350,921.88 | 25,503,374.19 | 141,924.17 |
| 减:营业外支出 | 174,400.14 | 1,183,966.55 | 1,066,496.32 | 65,202.68 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 116,834,898.9 | 203,523,478.93 | 218,776,319.04 | 134,760,019.43 |
| 减:所得税费用 | 15,488,195.37 | 24,851,439.77 | 31,123,994.74 | 21,090,036.45 |
| 六、净利润 | 101,346,703.53 | 178,672,039.16 | 187,652,324.3 | 113,669,982.98 |
| 持续经营净利润 | 101,346,703.53 | 178,672,039.16 | 187,652,324.3 | 113,669,982.98 |
| 归属于母公司股东的净利润 | 104,108,160.35 | 181,860,747.32 | 197,855,106.96 | 119,025,836.94 |
| 少数股东损益 | -2,761,456.82 | -3,188,708.16 | -10,202,782.66 | -5,355,853.96 |
| (一)基本每股收益 | 0.08 | 0.14 | 0.15 | 0.09 |
| (二)稀释每股收益 | 0.08 | 0.14 | 0.15 | 0.09 |
| 八、其他综合收益 | -1,322,708.98 | 420,502.44 | -1,565,667.03 | -409,696.28 |
| 归属于母公司股东的其他综合收益 | -1,322,708.98 | 420,502.44 | -1,565,667.03 | -409,696.28 |
| 九、综合收益总额 | 100,023,994.55 | 179,092,541.6 | 186,086,657.27 | 113,260,286.7 |
| 归属于母公司股东的综合收益总额 | 102,785,451.37 | 182,281,249.76 | 196,289,439.93 | 118,616,140.66 |
| 归属于少数股东的综合收益总额 | -2,761,456.82 | -3,188,708.16 | -10,202,782.66 | -5,355,853.96 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-25 | 2023-07-22 |
| 审计意见(境内) | | 标准无保留意见 | | |